- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Chronic myeloid leukaemia (CML); Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL); Myelodysplastic or myeloproliferative disorder (MDS/MPD); Aggressive systemic mastocytosis (ASM) with eosinophilia; Chronic eosinophilic leukaemia (CEL) or Hypereosinophilic syndrome (HES); Dermatofibrosarcoma protuberans (DFSP); Gastrointestinal stromal tumour (GIST); Malignant GIST.
- Meeting Date: November 2021
- Public Summary Document (PSD) November 2021 PBAC Meeting - (PDF 404KB)
- Public Summary Document (PSD) November 2021 PBAC Meeting - (Word 55KB)
Imatinib – November 2021
Imatinib: Tablet 600 mg; Imatab®
Last updated
4 March 2022